Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Keyphrases

• Phase II Trial 100%
• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• First-line Therapy 100%
• Doravirine 100%
• Open-label Extension 100%
• Tenofovir Disoproxil Fumarate 17%
• Safety Profile 11%
• Drug Adverse Events 11%
• Lipid Profile 11%
• Once-daily 11%
• Darunavir 11%
• Antiretroviral Therapy 11%
• HIV RNA 11%
• Merck 11%
• Lamivudine 11%
• Emtricitabine 11%
• Nucleoside Reverse Transcriptase Inhibitors 11%
• Efavirenz 11%
• Adverse Events 5%
• Weight Gain 5%
• Estimated Glomerular Filtration Rate 5%
• Ritonavir 5%
• Creatinine Clearance 5%
• Creatinine 5%
• Laboratory Parameters 5%
• Virological Failure 5%
• Efficacy Profile 5%
• Safety Assessment 5%
• Virologically Suppressed 5%
• Resistance Development 5%
• HIV Viral Load 5%
• Soluble Sulfate 5%
• Switch Therapy 5%
• Atazanavir Sulfate 5%
• Active Comparator 5%
• Renal Adverse Events 5%
• SNaPshot Method 5%
• Ritonavir-boosted Darunavir 5%
• HIV-1 Treatment 5%

Medicine and Dentistry

• Human Immunodeficiency Virus 100%
• Doravirine 100%
• Adverse Event 23%
• Tenofovir Disoproxil 17%
• Lamivudine 11%
• Emtricitabine 11%
• Efavirenz 11%
• Darunavir 11%
• Glomerular Filtration Rate 5%
• Creatinine Clearance 5%
• Creatinine 5%
• Antiretroviral Therapy 5%
• Reverse-Transcriptase Inhibitor 5%
• Drug Screening 5%
• Nucleoside 5%
• Ritonavir 5%
• Abacavir 5%
• Safety Assessment 5%
• Darunavir Plus Ritonavir 5%
• Acivicin 5%

Pharmacology, Toxicology and Pharmaceutical Science

• HIV 100%
• Doravirine 100%
• Adverse Event 23%
• Tenofovir Disoproxil 17%
• Creatinine 11%
• Darunavir 11%
• Lamivudine 11%
• Emtricitabine 11%
• Efavirenz 11%
• Ritonavir 5%
• RNA Directed DNA Polymerase Inhibitor 5%
• Nucleoside 5%
• Drug Screening 5%
• Abacavir 5%
• Safety Assessment 5%
• Acivicin 5%
• Darunavir Plus Ritonavir 5%